Notably, combination treatment of CD26Her2 mouse tumors with targeted therapy (anti-erbB2/neu antibody) plus a PRMT5 inhibitor (DS-437) enhanced anti-tumor effects through Treg suppression and augmented anti-tumor immunity [103]. Here, ERBB2 is linked to neoplasm.